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Abstract
Background: Plasmodium vivax is the most prevalent cause of human malaria in tropical regions outside the
African continent. The lack of a routine continuous in vitro culture of this parasite makes it difficult to develop
specific drugs for this disease. To facilitate the development of anti-P. vivax drugs, bacterial and yeast
surrogate models expressing the validated P. vivax target dihydrofolate reductase-thymidylate synthase (DHFR-
TS) have been generated; however, they can only be used as primary screening models because of significant
differences in enzyme expression level and in vivo drug metabolism between the surrogate models and P.
vivax parasites.
Methods: Plasmodium falciparum and Plasmodium berghei parasites were transfected with DNA constructs
bearing P. vivax dhfr-ts pyrimethamine sensitive (wild-type) and pyrimethamine resistant (mutant) alleles. Double
crossover homologous recombination was used to replace the endogenous dhfr-ts of P. falciparum and P.
berghei parasites with P. vivax homologous genes. The integration of Pvdhfr-ts genes via allelic replacement was
verified by Southern analysis and the transgenic parasites lines validated as models by standard drug screening
assays.
Results: Transgenic P. falciparum and P. berghei lines stably expressing PvDHFR-TS replacing the endogenous
parasite DHFR-TS were obtained. Anti-malarial drug screening assays showed that transgenic parasites expressing
wild-type PvDHFR-TS were pyrimethamine-sensitive, whereas transgenic parasites expressing mutant PvDHFR-TS
were pyrimethamine-resistant. The growth and sensitivity to other types of anti-malarial drugs in the transgenic
parasites were otherwise indistinguishable from the parental parasites.
Conclusion: With the permanent integration of Pvdhfr-ts gene in the genome, the transgenic Plasmodium lines
expressing PvDHFR-TS are genetically stable and will be useful for screening anti-P. vivax compounds targeting
PvDHFR-TS. A similar approach could be used to generate transgenic models specific for other targets of interest,
thus facilitating the development of anti-P. vivax drugs in general.
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Current anti-malarial drug development efforts are
focused on screening for lead compounds against Plas-
modium falciparum, the most lethal species. Plasmo-
dium falciparum can be routinely cultured in vitro and
is thus amenable to high throughput compound screen-
ing. Anti-malarial drug development against other
human Plasmodium species, particularly Plasmodium
vivax - which is the most prevalent cause of human
malaria in tropical regions, with an estimated 80 million
cases annually [1], is neglected in comparison, since
continuous in vitro culture methods are not available
for these species. The morbidity and mortality caused by
P. vivax infection are greater than previously believed
[2]. Chloroquine has been used as the standard treat-
ment for blood stage vivax malaria for more than 40
years; however, chloroquine-resistant P. vivax has been
reported in many parts of the world [3-5]. Therefore,
there is an urgent need for new anti-vivax anti-malarial
drugs.
One of the validated drug targets for the treatment of
malaria infection is dihydrofolate reductase (DHFR;
EC1.5.1.3), an essential enzyme for folate biosynthesis
[6,7]. The efficacy of current anti-folate drugs targeting
Plasmodium DHFR is compromised by mutations in the
dhfr gene, which confer different levels of resistance to
these drugs [8-10]. Point mutations in the P. vivax dhfr
gene equivalent to antifolate resistance mutations found
in P. falciparum have been associated with antifolate
resistance in P. vivax in vitro [11-13], leading to the
conclusion that wild-type P. vivax is sensitive to antifo-
lates, and resistance develops through dhfr mutations,
similar to the case in P. falciparum.
Despite the emergence of drug-resistant dhfr mutants,
DHFR-TS is still an attractive target for anti-malarial
drug development owing to the availability of target-
based screening models and crystal structures of both P.
falciparum [14] and P. vivax DHFR enzymes [15]. How-
ever, unlike P. falciparum, the development of antifo-
lates directed against P. vivax has been hampered by the
lack of a continuous in vitro parasite culture system.
Clinical isolates can only be cultured for a short period
of time [16,17]. Furthermore, mixed infection with other
human malaria parasites can also complicate the drug
screening results of clinical isolates. Recently, a P. vivax
in vitro culture system using erythroblasts has been
developed [18], but it is not practical for use in routine
drug screening assay.
Surrogate cell expression systems expressing PvDHFR
enzymes in yeast [19] and bacteria [20] have been devel-
oped as alternatives to parasite drug screening. However,
these surrogate systems are of limited use since the level
of target enzyme expression and mechanisms of drug
metabolism differ markedly from Plasmodium parasites.
A physiologically similar Plasmodium species is clearly a
more attractive P. vivax surrogate, and this has been
proven using transfection technology in which P. falci-
parum parasites expressing mutant PvDHFR-TS have
been shown to recapitulate the mutant PvDHFR-TS
antifolate resistance [21]. In the same manner, trans-
genic P. falciparum parasites episomally expressing drug
resistant PvDHFR-TS mutant enzymes have also been
developed for studying P. vivax drug resistance. How-
ever, these transgenic P. falciparum parasites still
express endogenous PfDHFR-TS as well as episomally
expressed PvDHFR-TS enzymes [22], which could con-
found drug screening results.
In order to facilitate antifolate screening specifically
against PvDHFR-TS, transgenic P. falciparum and Plas-
modium berghei parasites stably expressing PvDHFR-TS
enzyme replacing the endogenous Pf or PbDHFR-TS
were generated. These transgenic lines were evaluated as
in vitro and in vivo Plasmodium models for direct
assessment of the antifolate efficacy against PvDHFR-
TS. These Plasmodium surrogate models were thus vali-
dated as alternative tools for screening PvDHFR-TS-tar-
geted compounds.
Methods
Parasites
Plasmodium falciparum strains TM4/8.2 (wild-type
DHFR) and K1CB1 (mutant DHFR at residues C59R
+S108N) were gifts from Sodsri Thaithong, Faculty of
Science, Chulalongkorn University, Thailand. Pyri-
methamine-resistant strain K1CB1 was used as paren-
tal parasite to generate an in vitro P. vivax screening
model. The parasites were maintained continuously in
human erythrocytes at 37°C under 5% CO2,1 %O 2 and
94% N2 in RPMI-1640 culture media supplemented
with 24 mM NaHCO3,4 0μg/mL gentamicin, 25 mM
HEPES and 10% human serum [23]. For generation of
in vivo screening models, the transgenic P. berghei
parasite line MRA-867 (PbGFP), a gift from Chris
Janse and Andy Waters at Leiden University Medical
Center, the Netherlands, was used. This line contains
the gfp gene stably integrated as a single copy by dou-
ble cross-over recombination into the 230p locus, and
does not contain a drug selectable marker gene
[24,25]. Frozen parasites from stock were mechanically
passaged at least once through female BALB/c mice
before experiments. Animals were bled from the heart
and parasitaemia measured by Giemsa-stained thin
blood smear. Infected erythrocytes were suspended in
PBS and infection for experiments was carried out by
intra-peritoneal injection of approximately 1 × 10
7
parasitized erythrocytes.
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Pathogen-free, six-week-old female BALB/c mice
weighing 20-30 g were obtained from the National
Laboratory Animal Center, Mahidol University, Thai-
land. They were kept for at least one week with tap
water and pellet diet (CP diet 082, Perfect Companion
Company, Bangkok, Thailand) ad libitum at 22-25°C
and a 12-hour light/12-hour dark cycle. Experiments
were started in seven- to eight-week-old animals. Ani-
mal experiments were ratified by the Ethical Commit-
tee on Animal Experimentation, Faculty of Medicine,
Chiang Mai University, Chiang Mai, Thailand and by
the Ethical Committee on Animal Experimentation,
National Center for Genetic Engineering and Biotech-
nology (BIOTEC), Thailand. Animal experiments con-
formed to international and national guidelines for
ethical conducts on the care and humane use of
animals.
Construction of transfection plasmids
Wild-type and mutant P. vivax dhfr-ts genes were kindly
given by Ubolsree Leartsakulpanich, BIOTEC, Thailand
[11]. For generation of transgenic P. falciparum parasite
stably expressing PvDHFR-TS, a transfection plasmid
was constructed containing three expression cassettes:
1) blasticidin-S deaminase (bsd) as a positive selection
marker under the control of 5’ flanking region of P. fal-
ciparum camodulin gene (Pfcam) and 3’ UTR of P. falci-
parum histidine rich protein 2 (Pfhrp2) [26], 2) A fusion
gene of cytosine deaminase and uracil phosphoribosyl
transferase (yfcu)f r o mSaccharomyces cerevisiae as a
negative selection marker under the control of 5’ flank-
ing region of P. falciparum heat shock protein 86 gene
(Pfhsp86)a n d3 ’ UTR of P. berghei dihydrofolate reduc-
tase (Pbdhfr)[ 2 7 ] ,a n d3 )T h ew i l d - t y p edhfr-ts gene of
P. vivax under the control of 5’ flanking region of Pfdhfr
and 3’ UTR of Pfhrp2 (Figure 1A). The 5’ flanking
region and truncated 5’ coding sequence of Pfdhfr-ts are
the sites for homologous recombination and replace-
ment of Pfdhfr-ts with Pvdhfr-ts gene in the P. falci-
parum parasite chromosome 4.
Plasmodium berghei transfection plasmids were con-
structed from plasmids pL0017 [24] and pL0035 [28],
w h i c hw e r ek i n d l yp r o v i d e db yC h r i sJ a n s ea n dA n d y
Waters (Leiden University Medical Center, the Nether-
lands). In order to generate a P. berghei parasite line sta-
bly expressing wild-type PvDHFR-TS enzyme,
transfection plasmids were modified to consist of two
expression cassettes (Figure 1B). The first cassette has
the wild-type Pvdhfr-ts gene flanked by 5’ and 3’UTR
Pbdhfr-ts gene sequences. The second cassette is a drug
selection cassette containing a fusion gene of positive
(human dihydrofolate reductase; hdhfr) and negative
(yeast yfcu) selectable markers under the control of 5’
flanking region of P. berghei elongation factor 1a-a
(Pbef1a-a) and 3’UTR sequence of Pbdhfr-ts gene.
For generation of P. berghei parasite stably expressing
double mutant (S58R+S117N; SP21) PvDHFR-TS
enzyme, the transfection plasmid contains the double
mutant Pvdhfr-ts gene (Pvsp21) flanked by the Pbdhfr-ts
gene 5’ and 3’ flanking sequences (Figure 1C). The
Pbdhfr-ts gene sequences serve as the sites for double-
crossover homologous recombination. The pyrimetha-
mine-resistant Pvsp21 gene itself serves as a positive
drug selectable marker for integration and gene
replacement.
Generation of transgenic parasite lines stably expressing
PvDHFR-TS
Plasmodium falciparum transfection
Transfection of P. falciparum parasite was performed
following a standard protocol [29]. Briefly, synchronized
ring stage P. falciparum parasite strain K1CB1 (pyri-
methamine-resistant) was transfected with 100 µg of
transfection plasmid by electroporation (0.2 cm-gap
electroporation cuvette, 0.310 kV, 950 µF). The trans-
genic parasites were first selected with blasticidin. Once
blasticidin-resistant parasites were obtained, they were
further treated with the negative selectable drug 5-fluor-
ocytosine (5-FC) to select for double crossover integra-
tion of Pvdhfr-ts gene replacing the endogenous Pfdhfr-
ts gene. After several rounds of drug cycling, stable
transgenic parasites with the desired integration event
were obtained and cloned by limiting dilution.
Plasmodium berghei transfection
Transfection of P. berghei parasites was performed using
an Amaxa Nucleofector device (Amaxa), following the
standard protocol [30]. Purified schizonts of GFP-
expressing P. berghei ANKA parasite line MRA-867
(PbGFP) were transfected with 10 µg of linearized trans-
fection plasmid in 100 µl of Human T Cell Nucleofector
solution (Amaxa) using programme U-33, and then
injected intravenously into naïve BALB/c recipient mice.
Twenty-four hours post-injection, blood smears were
made from the host animals and the presence of para-
sites checked by Giemsa staining. Drug-resistant para-
sites were selected by pyrimethamine administered to
the drinking water (70 µg/ml). Under this selection regi-
men, PvDHFR-TS SP21 conferred pyrimethamine resis-
tance to transgenic parasites. For selection of P. berghei
harbouring wild-type Pvdhfr-ts,a f t e rp y r i m e t h a m i n e
selection for the positive drug marker hdhfr,i n f e c t e d
mice were injected intra-peritoneally twice a day with 5-
FC (dissolved in 0.9% NaCl) at 1 g/kg bodyweight for a
period of three days to select for parasites in which the
drug selectable markers had been excised by single
homologous recombination via the Pbdhfr-ts 3’UTR
repeated sequence elements [28], whilst retaining the
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transgenic P. berghei parasites were subsequently cloned
by the method of limiting dilution [31].
Characterization of transgenic parasites
Correct integration of the constructs into the host’s
endogenous dhfr-ts locus was demonstrated by Southern
analysis of restricted genomic DNA from transgenic
parasites. Genomic DNA from erythrocytes infected
with transgenic P. falciparum harbouring Pvdhfr-ts gene
w a sp u r i f i e du s i n gaQ I A a m pB l o o dM i n iK i t( Q i a g e n )
according to the manufacturer’s instructions. Blood
from mice infected with transgenic P. berghei harbour-
ing Pvdhfr-ts or Pvsp21 genes was collected by cardiac
puncture, and then depleted of leucocytes by passing
through a CF11 cellulose column (Whatman). Following
lysis of the erythrocyte pellet with 0.2% (w/v) saponin in
PBS, total genomic DNA from parasites was obtained
using a QIAamp Blood Mini Kit (Qiagen). The resulting
DNA was then used for Southern analysis to confirm
allelic replacement of the endogenous dhfr-ts with the P.
vivax homologue. Briefly, 30 µg of genomic DNA from
transgenic parasites was restriction-digested, separated
in 0.6% (w/v) agarose gel and transferred onto a Hybond
Figure 1 Diagrammatic representation of strategy to generate transgenic parasites by homologous recombination of Pvdhfr-ts gene
replacing endogenous dhfr-ts locus. (A) Generation of transgenic P. falciparum stably expressing wild-type PvDHFR-TS. The endogenous Pfdhfr-
ts locus was targeted via double homologous recombination with a plasmid containing expressing cassettes of wild-type Pvdhfr-ts, and
blasticidin-S deaminase (bsd) marker. Yeast cytosine deaminase-uracil phosphoribosyl transferase (yfcu) was used as negative selectable marker. (B)
Generation of transgenic P. berghei stably expressing wild-type PvDHFR-TS. The endogenous Pbdhfr-ts locus was targeted with a linearized
plasmid containing expressing cassettes of wild-type Pvdhfr-ts, and fusion gene of human dhfr (hdhfr) and yeast yfcu as positive and negative
selectable markers respectively. After double homologous recombination, the drug selectable markers are excised by single homologous
recombination via the Pbdhfr-ts 3’UTR repeated sequence elements (blue boxes), whilst retaining the wild-type Pvdhfr-ts gene. (C), Generation of
transgenic P. berghei stably expressing mutant PvDHFR-TS SP21. The endogenous Pbdhfr-ts locus was targeted with a linearized plasmid
containing expressing cassettes of mutant Pvdhfr-ts sp21 (Pvsp21) flanked with 5’ and 3’ UTR of Pbdhfr-ts which also serve as the sites for double
homologous recombination. Specific probes for Southern analysis are located by bold horizontal line. E: EcoRI, H: HindIII, K: KpnI.
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ting. Digested DNA was fixed to the membrane by UV
cross-linking and hybridized with specific probes pre-
pared with a DIG labelling kit (Roche Applied Science).
All probes used in this study are shown schematically in
Figure 1. The pattern of hybridization was detected
using alkaline phosphatase-conjugated anti-DIG anti-
body and CSPD reagent according the manufacturer’s
instructions (Roche Applied Science).
Validation of transgenic parasites as models for PvDHFR-
TS screening
SYBR Green I assay
Plasmodium falciparum strains TM4/8.2, K1CB1 and
transgenic P. falciparum expressing PvDHFR-TS were
maintained in human erythrocytes as previously
described and synchronized to 1% ring stages at 2% hae-
matocrit. Ninety microliters of cultured parasites were
transferred to each well of a 96-well microtitre plate
before 10 μl of pyrimethamine (Sigma), chloroquine
(Sigma) and dihydroartemisinin (a gift from Dafra
Pharma International) at different concentrations were
added in triplicate. The mixtures were incubated at 37°C
under 5% CO2,1 %O 2 and 94% N2 for 48 hours. To
determine parasite growth, 100 μlo fS Y B Rg r e e nI( a t
1:5,000 dilution in culture media; Invitrogen) was added
to the culture mixtures for 30 minutes at room tem-
perature in the dark [32]. The SYBR green I-stained
parasitized erythrocytes were then analysed using a
Cytomics 500 FC MPL flow cytometer (Beckman Coul-
ter) equipped with a 96-well plate adaptor. Erythrocytes
were identified on the basis of their specific forward
(FSC) and side (SSC) light-scattering properties. The
green fluorescence signal was excited with an argon ion
laser at a wavelength of 488 nm and the emission of the
green fluorescence was detected using a 530/30 nm
band pass filter. A previous analysis of non-infected ery-
throcytes was performed to determine a cut off for
these cells to distinguish them from parasitized cells.
The fluorescent intensity of a total of 100,000 events per
sample was measured and data analysis was subse-
quently performed using CXP software (Beckman Coul-
ter). For calculation of the percentage of parasite
growth, the mean parasitaemia of untreated parasites
was set at 100% growth. The concentration of drugs
that inhibits 50% of the parasite growth (IC50)w a s
determined from the sigmoidal curve obtained by plot-
ting the percentages of parasite growth against drug
concentrations.
GFP assay
In order to validate transgenic P. berghei parasite stably
expressing PvDHFR-TS enzymes as in vivo models for
antifolate drug screening, the assessment of anti-malarial
drug efficacy in vivo was performed using the standard
four-day suppressive test [33]. Groups of at least three
mice were inoculated with approximately 1 × 10
7 parasi-
tized erythrocytes intravenously and then treated with
standard anti-malarials: pyrimethamine (Sigma), chloro-
quine (Sigma) or artesunate (Mekophar Chemical Phar-
maceutical) once daily for four successive days from the
day of parasite inoculation. The drugs at chosen doses
(mg/kg of body weight) were freshly prepared in 100%
DMSO (pyrimethamine and artesunate) or distilled
water (chloroquine) and administered orally by gavage.
It was found that pyrimethamine at 50 mg/kg was lethal
to mice as all animals died soon after treatment with
this dose by oral administration (data not shown).
Hence, the maximum pyrimethamine dose was 30 mg/
kg. Untreated controls were given either distilled water
or DMSO only. The course of parasitaemia in untreated
mice (control group) and in mice treated with different
doses of drugs was monitored by flow cytometry since
these parasites express GFP as fluorescence marker. A
drop of blood was collected directly into wells of a 96-
well microtitre plate containing 200 µl of RPMI-1640
culture media and heparin (1U/µl). The GFP signal in
these samples was measured as described above. For cal-
culation of the growth inhibitory curves, the mean para-
sitaemia of the control samples was set at 0% inhibition.
The concentration of drugs that inhibits 50% of the
parasite growth (ED50) was determined from the sigmoi-
dal curve obtained by plotting the percent parasite
growth inhibition against drug concentrations.
Statistical analysis
Parasites’ growth and growth inhibitory curves and sta-
tistical analysis of the data were performed using the
GraphPad Prism software version 5.0 (GraphPad Soft-
ware). The non-linear regression function for sigmoidal
dose-response (variable slope) was used to calculate the
best-fit 50% inhibition concentration (IC50) or 50%
effective concentration (EC50) values.
Results
Generation of transgenic Plasmodium falciparum
harbouring Pvdhfr-ts gene
Pyrimethamine-resistant P. falciparum strain K1CB1
was transfected with plasmid DNA for replacement of
the endogenous Pfdhfr-ts with wild-type Pvdhfr-ts.F o l -
lowing rounds of positive and negative selections, trans-
genic P. falciparum were obtained. A clonal parasite line
designated PfPvDTclB2 was obtained and gene replace-
ment verified by Southern blotting analysis. As shown in
Figure 2A, hybridization with a Pvdhfr-ts DNA probe
showed the expected 3.7 kb and 5.9 kb EcoRI-digested
fragments from transgenic PfPvDTclB2 genomic DNA
and control plasmid DNA, respectively, confirming the
integration of Pvdhfr-ts at the correct site, while no
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line. Another DNA probe specific to Pfdhfr could detect
the expected 8.8 kb, 8.0 kb and 5.4 kb EcoRI-digested
fragments from genomic DNA of transgenic
PfPvDTclB2, parental P. falciparum K1CB1 line and
control plasmid DNA, respectively. From these results,
it can be concluded that transgenic PfPvDTclB2 para-
sites stably express wild-type Pvdhfr-ts instead of endo-
genous Pfdhfr-ts; furthermore, these parasites are clonal,
lack episomal plasmid DNA and can be stably main-
tained without drug selection.
Generation of transgenic Plasmodium berghei harbouring
Pvdhfr-ts gene
Blood stages of the reference GFP-expressing P. berghei
parasite line PbGFP were transfected with the linear
form of the transfection vectors by electroporation in
order to introduce either wild-type Pvdhfr-ts or mutant
Pvsp21 genes replacing the endogenous Pbdhfr-ts gene.
For selection of P. berghei harbouring wild-type Pvdhfr-
ts, a two-step drug selection procedure was performed.
First, transgenic parasites with integrated wild-type
Pvdhfr-ts were selected with pyrimethamine. Subse-
quently, negative selection was performed to select for
parasites which had excised the positive-negative drug
selection cassette in order to obtain parasites that have
only wild-type Pvdhfr-ts gene integrated to the P. ber-
ghei genome (Figure 1B). Transgenic P. berghei parasite
clones stably expressing wild-type PvDHFR-TS (desig-
nated PbPvDTcl4) or double mutant PvDHFR-TS SP21
(designated PbPvSP21cl2) were obtained and analysed
by Southern blotting. As shown in Figure 2B, the KpnI/
HindIII digested genomic DNA fragments correspond-
ing to the parental wild type and transgenic P. berghei
parasites (1.5 kb and 3.3 kb, respectively) were detected
by a DNA probe specific to 3’UTR Pbdhfr-ts.T h u s ,t h i s
confirmed the successful generation of transgenic P. ber-
ghei parasites stably harbouring wild-type Pvdhfr-ts or
mutant Pvsp21, replacing the endogenous Pbdhfr-ts
gene.
Drug sensitivity analysis of transgenic Plasmodium
falciparum stably expressing wild-type PvDHFR-TS
enzyme
Transgenic PfPvDTclB2 parasite was evaluated against
standard anti-malarial drugs. Pyrimethamine is the stan-
dard antifolate drug and used as the primary compound
to validate this system. As shown in Figure 3A and
Table 1, the transgenic PfPvDTclB2 parasite was much
more sensitive to pyrimethamine than the parental
K1CB1 line, verifying that the wild-type Pvdhfr-ts gene
replacing the Pfdhfr-ts gene is a pyrimethamine-sensitive
variant. Moreover, the level of pyrimethamine sensitivity
in the transgenic PfPvDTclB2 parasite is the same as the
antifolate-sensitive P. falciparum TM4/8.2 strain (IC50 =
0.03 ± 0.02 µM). The parental K1CB1 line is also resis-
tant to chloroquine, a 4-aminoquinoline drug that inhi-
bits haemozoin formation in the food vacuole of the
parasites. This transgenic PfPvDTclB2 line shows the
same chloroquine-resistant phenotype as the parental P.
falciparum K1CB1 strain, with IC50 values of 49.5 ± 5.8
nM and 46.0 ± 3.1 nM respectively (Figure 3B and
Table 1), indicating that the dhfr-ts gene replacement
did not affect sensitivity to drugs not targeting DHFR-
TS. Another non-antifolate drug control used in this
study was dihydroartemisinin (DHA). All parasites
tested in this study were sensitive to DHA at the IC50
values of 0.6 ± 0.1 nM, 0.7 ± 0.3 nM and 0.4 ± 0.1 nM
for P. falciparum TM4/8.2, K1CB1 and transgenic
PfPvDTclB2, respectively (Figure 3C and Table 1).
Figure 2 Southern analysis of transgenic parasites to confirm allelic replacement of dhfr-ts of Plasmodium falciparum (A) and
Plasmodium berghei (B) with dhfr-ts gene from P. vivax. DNA probes specific to Pvdhfr-ts (PvDT), Pfdhfr (PfD) and 3’UTR of Pbdhfr-ts (3’UTR
PbDT) were used to detect restriction-digested fragments from genomic DNA of transgenic parasites. Pl: pCBVD plasmid control; K1: P. falciparum
K1CB1; B2: Transgenic PfPvDTclB2; PbGFP: P. berghei GFP; WT: transgenic PbPvDTcl4; SP: transgenic PbPvSP21cl2.
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berghei stably expressing PvDHFR-TS enzymes
After inoculation, mice in the untreated control group
showed a progressively increasing parasitaemia, and all
the mice died by day 11 (data not shown). As shown in
Figure 4A and Table 1, the transgenic PbPvDTcl4
demonstrated a drug susceptibility profile similar to that
of the wild-type parental PbGFP with an ED50 of 0.53 ±
0.24 mg/kg and 0.69 ± 0.21 mg/kg, respectively. This
demonstrated that the wild-type PvDHFR-TS enzyme
was equally susceptible to the antifolate compound
compared with wild-type PbDHFR-TS. In contrast,
transgenic PbPvSP21cl2 was approximately 40-fold more
resistant to pyrimethamine than the PbPvDTcl4 parasite
line (Figure 4A). Therefore, the double mutant P. vivax
DHFR-TS confers a high level of resistance to pyri-
methamine in P. berghei.
The transgenic P. berghei lines were also tested with
the non-antifolate drugs chloroquine and artesunate. As
shown in Figure 4B and Table 1, all parasite lines were
similarly susceptible to chloroquine. The ED50 values
against chloroquine were 1.56 ± 0.12 mg/kg, 2.85 ± 0.17
mg/kg, and 3.88 ± 0.13 mg/kg mg/kg in parental
PbGFP, PbPvDTcl4 and PbPvSP21cl2 parasites, respec-
tively. Artesunate is extremely potent against pyrimetha-
mine-resistant parasites. It is a semi-synthetic derivative
of artemisinin that is water-soluble and may therefore
be given by injection. All parasite lines were also suscep-
tible to artesunate treatment with ED50 values of 5.43 ±
0.42 mg/kg, 7.43 ± 0.30 mg/kg and 7.59 ± 0.33 mg/kg
in parental PbGFP, PbPvDTcl4 and PbPvSP21cl2 para-
sites, respectively (Figure and Table 1).
Discussion and Conclusions
This study describes the generation of both in vitro and
in vivo transgenic Plasmodium parasites stably expres-
sing P. vivax DHFR-TS enzyme and the application of
these parasites for assessing antifolate compound effi-
cacy. The transgenic Plasmodium parasites harbour only
one copy of Pvdhfr-ts gene, which is under the control
of the endogenous dhfr-ts regulatory sequences. The
fact that it is possible to replace the endogenous Plas-
modium dhfr-ts with a homologue from a different spe-
cies suggests that dhfr-ts function is conserved among
species of this genus. This is in agreement with bio-
chemical evidence that cross-species heterodimers of
Plasmodium DHFR-TS are fully functional [34]. While
the expression of double mutant PvDHFR-TS SP21 was
not deleterious and can support the growth of the trans-
genic P. berghei parasites, attempts to obtain P. falci-
parum stably expressing double mutant PvDHFR-TS
SP21 were not successful (data not shown). The reasons
may be the catalytic activity of PvDHFR-TS SP21 is
insufficient to support the growth of transgenic P. falci-
parum. It was reported that the catalytic activity, as
determined by kcat/Km of H2folate,o fPvDHFR SP21 is
approximately 13 times and 27 times lower than that of
Figure 3 Sensitivity of transgenic Plasmodium falciparum
expressing wild-type PvDHFR-TS enzyme to pyrimethamine (A),
chloroquine (B) and dihydroartemisinin (C). The growth of
parasites treated with pyrimethamine, chloroquine and
dihydroartemisinin was detected using the SYBR Green I staining
assay. The percentage of parasite growth was plotted against drug
concentrations. Data were shown as mean ± S.D. of at least 3
independent experiments. K1: P. falciparum K1CB1; TM4: P.
falciparum TM4/8.2; B2: transgenic PfPvDTclB2.
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respectively.
A major advantage of the Pvdhfr-ts transgenic para-
sites generated in the study is that the gene is stably
maintained in an integrated fashion. This issue is impor-
tant since it has been reported that the apparent copy
number of plasmid DNA in episomally transfected Plas-
modium is variable, which may affect the drug sensitivity
profile in drug testing assays. The reasons for varying
copy numbers are related to the nature of the episomal
plasmid itself and the level and duration of drug pres-
sure [36]; moreover, higher drug concentration are
known to select for increased copy numbers of the epi-
some [37]. In the absence of drug pressure, both trans-
genic P. falciparum and P. berghei lose episomal
transgenes [36,38,39]; hence, constant drug pressure is
needed to maintain the episomes. In the earlier report
of P. falciparum episomally expressing Pvdhfr-ts,n o
effect of episomal copy number on the drug sensitivity
profile was observed, probably owing to the tight regula-
tion of the parasite DHFR-TS expression level [22,40].
However, the episomal copy number did vary since the
drug used to maintain the episome must be withdrawn
for compound testing, hence the episomal system may
not be sufficiently robust as a general drug screening
method.
In this study, in vitro and in vivo Plasmodium models
have been generated specifically for anti-PvDHFR
screening. There are reports that compounds that have
anti-P. falciparum activity in in vitro screening do not
s h o wt h es a m ea n t i - Plasmodial activity in in vivo mod-
els, such as P. berghei [41,42]. It is therefore premature
to assume that compounds found to be active in vitro
will also be efficacious in vivo before pharmacokinetic
studies of the compounds in animal models have been
conducted, since compounds with poor pharmacokinetic
properties may simply not reach their targets. At pre-
sent, the only in vivo model for P. vivax is P. cynomolgi
infecting primates [43]. This model is expensive and
Table 1 Drug sensitivity of transgenic Plasmodium expressing PvDHFR-TS to standard anti-malarials
P. falciparum IC50 ± S.D.
Pyrimethamine (µM) Chloroquine (nM) Dihydroartemisinin (nM)
P. falciparum TM4/8.2 0.03 ± 0.02 4.3 ± 1.4 0.6 ± 0.1
P. falciparum K1CB1 28.7 ± 1.7 46.0 ± 3.1 0.7 ± 0.3
PfPvDTclB2 0.03 ± 0.02 49.5 ± 5.8 0.4 ± 0.1
P. berghei ED50 ± S.D. (mg/kg)
Pyrimethamine Chloroquine Artesunate
P. berghei GFP 0.69 ± 0.21 1.56 ± 0.12 5.43 ± 0.42
PbPvDTcl4 0.53 ± 0.24 2.85 ± 0.17 7.43 ± 0.30
PbPvSP21cl2 > 30 3.88 ± 0.13 7.59 ± 0.33
Figure 4 Sensitivity of transgenic Plasmodium berghei
expressing PvDHFR-TS enzyme to pyrimethamine (A),
chloroquine (B) and artesunate (C). The transgenic parasites were
validated using the standard four-day suppressive test. Percent
parasite inhibition was plotted for groups of at least five mice orally
given varying doses of pyrimethamine, chloroquine and artesunate.
Data were shown as mean ± S.D. of at least three independent
experiments.
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genic P. berghei expressing P. vivax targets is an attrac-
tive alternative experimental model.
In conclusion, transgenic P. falciparum and P. berghei
stably expressing PvDHFR-TS replacing the endogenous
Plasmodium dhfr-ts were successfully generated as in
vitro and in vivo Plasmodium drug screening models.
The drug sensitivities of the transgenic lines varied
according to the introduced Pvdhfr-ts gene. Until a rou-
tine continuous in vitro culture system is developed for
P. vivax, these transgenic models will be useful for
screening of anti-P. vivax compounds targeting the
PvDHFR enzyme. A similar approach could be used to
generate transgenic models specific for other targets of
interest, thus facilitating the development of anti-P.
vivax drugs in general.
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